Robert Aronstam

Dr. Robert Aronstam


Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2010 in Materials
Verified
Journal Article
Open access
PDF file
YHYue-Wern Huang
Yue-Wern Huang
CWChi-Heng Wu
Chi-Heng Wu
RARobert Aronstam
Robert Aronstam
Nanotechnology has evolved to play a prominent role in our economy. Increased use of nanomaterials poses potential human health risk. It is therefore critical to understand the nature and origin of the toxicity imposed by nanomaterials (nanotoxicity). In this article we review the toxicity of the transition metal oxides in the 4th period that are widely used in industry and biotechnology. Nanoparticle toxicity is compellingly related to oxidative stress and alteration of calcium homeostasis, gene expression, pro-inflammatory responses, and cellular signaling events. The precise physicochemical properties that dictate the toxicity of nanoparticles have yet to be defined, but may include element-specific surface catalytic activity (e.g., metallic, semiconducting properties), nanoparticle uptake, or nanoparticle dissolution. These in vitro studies substantially advance our understanding in mechanisms of toxicity, which may lead to safer design of nanomaterials.

12 February 1990 in FEBS Letters
Verified
Journal Article
Closed access
MAManickavasagom Alkondon
Manickavasagom Alkondon
Alberto CostaAlberto Costa
Alberto Costa
VRVeeraswamy Radhakrishnan
Veeraswamy Radhakrishnan
RARobert Aronstam
Robert Aronstam
EAEdson X. Albuquerque
Edson X. Albuquerque

1 March 1995 in Biochemical Pharmacology
Verified
Journal Article
Closed access
DMDan C. Martin
Dan C. Martin
MPMarc Plagenhoef
Marc Plagenhoef
JAJames Abraham
James Abraham
RDRobert L. Dennison
Robert L. Dennison
RARobert Aronstam
Robert Aronstam

1 September 1977 in Biochemical Pharmacology
Verified
Journal Article
Closed access
RARobert Aronstam
Robert Aronstam
LALeo G. Abood
Leo G. Abood
JBJesse Baumgold
Jesse Baumgold

1 February 1979 in Brain Research
Verified
Journal Article
Closed access
RARobert Aronstam
Robert Aronstam
CKCarol Kellogg
Carol Kellogg
LALeo G. Abood
Leo G. Abood

15 April 2009 in BMC Pharmacology
Verified
Journal Article
Open access
PDF file
RSRong Shi
Rong Shi
CHChuan-Chin Huang
Chuan-Chin Huang
RARobert Aronstam
Robert Aronstam
NENuran Ercal
Nuran Ercal
AMAdam Martin
Adam Martin
YHYue-Wern Huang
Yue-Wern Huang
Background: While doxorubicin (DOX) is widely used in cancer chemotherapy, long-term severe cardiotoxicity limits its use. This is the first report of the chemoprotective efficacy of a relatively new thiol antioxidant, N-acetylcysteine amide (NACA), on DOX-induced cell death in cardiomyocytes. We hypothesized that NACA would protect H9c2 cardiomyocytes from DOX-induced toxicity by reducing oxidative stress. Accordingly, we determined the ability of NACA to mitigate the cytotoxicity of DOX in H9c2 cells and correlated these effects with the production of indicators of oxidative stress. Results: DOX at 5 μM induced cardiotoxicity while 1) increasing the generation of reactive oxygen species (ROS), 2) decreasing levels and activities of antioxidants and antioxidant enzymes (catalase, glutathione peroxidase, glutathione reductase) and 3) increasing lipid peroxidation. NACA at 750 μM substantially reduced the levels of ROS and lipid peroxidation, as well as increased both GSH level and GSH/GSSG ratio. However, treating H9c2 cells with NACA did little to protect H9c2 cells from DOX-induced cell death. Conclusion: Although NACA effectively reduced oxidative stress in DOX-treated H9c2 cells, it had minimal effects on DOX-induced cell death. NACA prevented oxidative stress by elevation of GSH and CYS, reduction of ROS and lipid peroxidation, and restoration of antioxidant enzyme activities. Further studies to identify oxidative stress-independent pathways that lead to DOX-induced cell death in H9c2 are warranted.